Trials / Active Not Recruiting
Active Not RecruitingNCT06556368
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Three-arm Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 675 (estimated)
- Sponsor
- Kodiak Sciences Inc · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarcocimab tedromer | Intravitreal injection |
| DRUG | Tabirafusp tedromer | Intravitreal injection |
| DRUG | Aflibercept | Intravitreal injection |
Timeline
- Start date
- 2024-08-23
- Primary completion
- 2026-08-01
- Completion
- 2027-08-01
- First posted
- 2024-08-16
- Last updated
- 2025-10-27
Locations
72 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06556368. Inclusion in this directory is not an endorsement.